/ 2 items

#VSTM↓

VSTM/ 12/29/2025 · 4:24 PM

Verastem Stops Lung Cancer Trial to Focus on More Promising Treatment

Verastem Oncology discontinues RAMP 203 trial for KRAS G12C lung cancer to prioritize VS-7375, showing 69% response rate in KRAS G12D patients.

Variety of chemotherapy drugs in vials and an IV bottle.

SNDX/ 10/16/2025 · 10:25 AM

Wall Street Analysts Issue Buy Ratings on Five Cancer Treatment Companies

H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.